GenFleet gets China NMPA nod to start phase I/II trial of GFH375 to treat advanced solid tumour with KRAS G12D mutation
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced China's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS- …